López Cortés, Luis FernandoViciana Fernández, PompeyoGirón-González, José-AntonioRomero-Palacios, AlbertoMárquez-Solero, ManuelMartínez-Pérez, Maria A.Mohamed-Balghata, Mohamed O.2021-07-022021-07-022014-05-16López Cortés, L.F., Viciana Fernández, P., Girón-González, J., Romero-Palacios, A., Márquez-Solero, M., Martínez-Pérez, M.A. y Mohamed-Balghata, M.O. (2014). Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE, 9 (5), art. n. 97262.1932-6203 (electrónico)https://hdl.handle.net/11441/115072Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to ,50 copies/mL after 24 weeks on treatment, or a confirmed viral load .200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9–92.1%) and 77.4% (CI95, 65.0–89.7%), respectively; the rates reached 97.2% (CI95, 95.1–99.3%) and 90.5% (CI95, 81.7–99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1–2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity.application/pdf8 p.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Etravirine PlusNon-nucleoside reverse-transcriptase inhibitorsNNRTIsinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.1371/journal.pone.0097262